

In the Claims

Please amend the claims presented during the international phase as follows.

Applicant presents a full set of claims showing markups of the claims with insertions and deletions indicated by underlining (or double bracketing) and strikethrough text, respectively.

1. (Original) A method for delivering an anti-target compound to a subject for the treatment of a disorder without being inactivated by administering thereto a polypeptide construct comprising one or more single domain antibodies directed against said target.
2. (Currently amended) A method according to claim 1 wherein said target is located in the gut system, and said ~~[[a]]~~ polypeptide construct is delivered orally.
3. (Currently amended) A method according to claim 1 wherein said target is located in vaginal and/or rectal tract, and said ~~[[a]]~~ polypeptide construct is delivered to the vaginal and/or rectal tract.
4. (Currently amended) A method according to claim 1 wherein said target is located in nose, upper respiratory tract and/or lung, and said ~~[[a]]~~ polypeptide construct is delivered to nose, upper respiratory tract and/or lung.
5. (Currently amended) A method according to claim 1 wherein said target is located in intestinal mucosa, and said ~~[[a]]~~ polypeptide construct is delivered orally.
6. (Currently amended) A method according to claim 1 wherein said target is located in the tissues beneath the tongue, and said ~~[[a]]~~ polypeptide construct is delivered to the tissues beneath the tongue.
7. (Currently amended) A method according to claim 1 wherein said target is located in the skin, and said ~~[[a]]~~ polypeptide construct is delivered topically.
8. (Currently amended) A method according to claim 1 wherein said target is in, or accessible via the blood, and said ~~[[a]]~~ polypeptide construct is delivered orally, to the

vaginal and/or rectal tract, nasally, by inhalation through the mouth or nose, to the tissues beneath the tongue, or topically.

9. A polypeptide construct comprising at least one single domain antibody directed against a target, wherein the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 12 to 70, for use in treating, preventing and/or alleviating the symptoms of disorders which are susceptible to modulation by an anti-target therapeutic compound that is able to pass through the gastric environment without being inactivated.

10.-14. (Canceled)

15. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is TNF-alpha and the disorder is inflammation.

16. (Currently amended) A method ~~or polypeptide~~ according to claim 15, wherein ~~the~~ [[a]] the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 12 to 14.

17. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is CEA and the disorder is colon cancer.

18. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is EGFR and the disorder is any of head, neck, lung and colon cancer.

19. (Currently amended) A method ~~or polypeptide construct~~ according to claim 18, wherein ~~the~~ [[a]] the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 23 to 44.

20. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is antigen of *Helicobacter pylori* and the disorder is any of indigestion~~[[.]]~~ and gastritis.

21. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is antigen of *Mycobacterium tuberculosis* and the disorder is tuberculosis.
22. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is antigen of *influenza* virus and the disorder is flu.
23. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is antigen of MMP and the disorder is cancer.
24. (Currently amended) A method ~~or polypeptide construct~~ according to claim 23, wherein [[a]] the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 15 to 22.
25. (Currently amended) A method according to claim 1 ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~, wherein said target is an antigen of IFN-gamma and the disorder is any of cancer, transplant rejection, auto immune disorder.
26. (Currently amended) A method ~~or polypeptide construct~~ according to claim 25, wherein [[a]] the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 45 to 70.
27. (Currently amended) A method according to claim 1, ~~any of claims 1 to 8 or polypeptide construct according to any of claim 9 to 14~~ wherein said target is any of an antigen of *Helicobacter pylori*, an antigen of *Mycobacterium tuberculosis*, and an antigen of *influenza* virus.
28. (Currently amended) A polypeptide construct comprising (a) at least one single domain antibody directed against an internalising cellular receptor, and (b) at least one single domain antibody directed against a therapeutic target, or at least one therapeutic polypeptide or agent.

29. (Canceled)

30. (Currently amended) A polypeptide construct according to claim 28 ~~claims 28 or 29~~ wherein said internalising cellular receptor is Epidermal Growth Factor receptor.

31. (Original) A polypeptide construct according to claim 30 wherein a single domain antibody directed against an internalising cellular receptor corresponds to a sequence represented by SEQ ID NO: 23 to 44.

32. (Currently amended) A polypeptide construct according to claim 28 ~~claims 28 or 29~~ wherein said internalising cellular receptor is any of LDL receptor, FGF2[[r]] receptor, ErbB2[[r]] receptor, ~~transferring~~ transferrin receptor, ~~PDG~~ PDGF receptor, ~~VEG~~ VEGF receptor, or PsmAr.

33. (Currently amended) A polypeptide construct according to claim 28 ~~any of claims 28 to 32~~ wherein a single domain antibody directed against a therapeutic target, is directed against PDK1.

34. (Canceled)

35. (Currently amended) A polypeptide construct according to claim 28 ~~any of claims 28 to 32~~ wherein a single domain antibody directed against a therapeutic target is directed against any of GSK1, Bad, caspase and Forkhead.

36. (Canceled)

37. (Original) Method for delivering an anti-target therapeutic compound to the interior of a cell comprising administering to a subject a polypeptide construct according to claim 28 ~~any of claims 28 to 36~~.

38. (Canceled)

39. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in the gut system, and said ~~[[a]]~~ polypeptide construct is delivered orally.

40. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in vaginal and/or rectal tract, and said ~~[[a]]~~ polypeptide construct is delivered to the vaginal and/or rectal tract.

41. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in nose, upper respiratory tract and/or lung, and said ~~[[a]]~~ polypeptide construct is delivered to nose, upper respiratory tract and/or lung.

42. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in intestinal mucosa, and said ~~[[a]]~~ polypeptide construct is delivered orally.

43. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in the tissues beneath the tongue, and said ~~[[a]]~~ polypeptide construct is delivered to the tissues beneath the tongue.

44. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is located in the skin, and said ~~[[a]]~~ polypeptide construct is delivered topically.

45. (Currently amended) A method according to claim 37 ~~[[38]]~~ wherein said cell is in, or accessible via the blood, and said ~~[[a]]~~ polypeptide construct is delivered orally, to the vaginal and/or rectal tract, nasally, by inhalation through the mouth or nose, to the tissues beneath the tongue, or topically.

46. (Currently amended) A polypeptide construct according to any of claims 9 ~~or 28 to 44, 28 to 36~~, or as used in a method according to claim 1 ~~any of claims 1 to 8, 15 to 27, 37 to 45~~, wherein the single domain antibodies are humanized *Camelidae* VHHs, an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length single domain antibody, or wherein the polypeptide construct is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length polypeptide construct.

47.-49. (Canceled)

50. (Currently amended) A nucleic acid encoding a polypeptide construct according to any of claims 9 ~~to 14~~, 28 ~~to 36~~, or 46 ~~to 49~~.

51. (Currently amended) A composition comprising a polypeptide construct according to any of claims 9, 28 or 46 as defined in any of the preceding claims, together with a pharmaceutical carrier.

52. (New) A method according to claim 1, wherein said target is antigen of IgE and the disorder is allergic response.

53. (New) A method according to claim 52, wherein a single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 11.

54. (New) A polypeptide construct comprising at least one single domain antibody directed against IgE.

55. (New) A polypeptide construct according to claim 54 wherein at least one single domain antibody is a *Camelidae* VHH.

56. (New) A polypeptide construct according to claim 54 wherein at least one single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 11.

57. (New) A polypeptide construct according to claim 54, wherein the number of anti-IgE single domain antibodies is at least two.

58. (New) A polypeptide construct according to claim 57, wherein at least one single domain antibody is a humanized *Camelidae* VHH.

59. (New) A polypeptide construct according to claim 54, wherein a single domain antibody is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length single domain antibody.

60. (New) A polypeptide construct according to claim 54, wherein the polypeptide construct is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length polypeptide construct.
61. (New) A nucleic acid encoding a polypeptide construct according to claim 54.
62. (New) A method for treating and/or preventing and/or alleviating disorders relating to inflammatory processes comprising administering to a subject in need of such treatment a polypeptide construct according to claim 54.
63. (New) A composition comprising a polypeptide construct according to claim 54 together with a pharmaceutical carrier.